Citizens Maintains Market Outperform on Zevra Therapeutics, Raises Price Target to $28
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
Citizens analyst Jason N. Butler maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Market Outperform and raises the price target from $25 to $28.
Citizens analyst Jason N. Butler maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Market Outperform and raises the price target from $25 to $28.